Drug Approvals, Breakthrough Treatments and Royalties - Research Report on Celgene Corporation, Onyx Pharmaceuticals, Sarepta

  Drug Approvals, Breakthrough Treatments and Royalties - Research Report on
  Celgene Corporation, Onyx Pharmaceuticals, Sarepta Therapeutics, VIVUS and
                          Achillion Pharmaceuticals

PR Newswire

NEW YORK, March 8, 2013

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Sarepta
Therapeutics, Inc. (NASDAQ: SRPT), VIVUS Inc. (NASDAQ: VVUS) and Achillion
Pharmaceuticals, Inc. (NASDAQ: ACHN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celgene Corporation Research Report

The optimism for Celgene has been pushing the stock to trade on the green in
recent sessions. Celgene was hailed by the European Organization for Rare
Diseases (EURODIS) for its excellence in medical innovation in rare diseases.
The company is now considered as the leader in the treatment of rare
illnesses, such as cancer and other severe, immune and inflammatory
conditions. Celgene also received positive results for oral Apremilast after
it achieved statistical significance for the primary endpoint of PASI-75 in
the first Phase III study (ESTEEM 1) in patients with Psoriasis. Celgene is
expecting annual revenue of $12 billion by 2017. The Full Research Report on
Celgene Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge
at:[http://www.Investors-Alliance.com/r/full_research_report/d457_CELG ]

--

Onyx Pharmaceuticals, Inc. Research Report

After Onyx reported new sales record for its Kyprolis, the company's first
wholly-owned product, carcinoma-treatment Nexavar posted strong regional
growth as it exceeded $1 billion in sales. Onyx looks poised for long-term
growth after the US Food and Drug Administration (FDA) approved Stivarga. In
2012, Onyx received $8 million in royalty revenues from Bayer for the total
sales of Stivarga. The FDA approval is expected to rake in bigger royalties
for Onyx while the company continues its research and development for
breakthrough treatments. The Full Research Report on Onyx Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/ffcf_ONXX]

--

Sarepta Therapeutics, Inc. Research Report

Finding a treatment for Marburg Virus, a severe and potentially fatal disease
classified as a Category A bioterrorism agent, is a great challenge to Sarepta
as it collaborates with the US Army Medical Research Institute to formulate a
cure for the hemorrhagic fever. Sarepta's AVI-7288 received positive results
after conducting a non-human primate study to test the efficacy of the drug.
The company administered AVI-7288 via intramuscular injection which is
considered as the best way to utilize the cure in a mass casualty situation.
The success of AVI-7288 is expected to be massive once it is approved by the
FDA since its major clients may include various governments and Africa where
Marburg Virus is considered an endemic. The Full Research Report on Sarepta
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/cfa4_SRPT]

--

VIVUS Inc. Research Report

Qsymia, considered as one of the most successful obesity treatments from
VIVUS, showed great results after a study on weight loss and cardiovascular
disease risk factors. VIVUS reported that weight loss resulting from treatment
with Qsymia helped the improvement of cholesterol, blood pressure and
triglycerides related conditions. The positive results were greater among
patients who recorded an average of 10% in weight loss. VIVUS is expected to
earn a bigger market share because of this breakthrough obesity treatment. The
Full Research Report on VIVUS Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:[http://www.Investors-Alliance.com/r/full_research_report/8ed8_VVUS]

--

Achillion Pharmaceuticals, Inc. Research Report

Achillion is conducting the Phase II clinical trial consisting of sovaprevir
and ACH-3102 during the second quarter of 2013. The company has been actively
working up its research and development to gain new approvals from the US Food
and Drug Administration (FDA). Achillion is one of the leading companies for
the research and development of Hepatitis C Virus (HCV) treatments. The
company is known for developing small molecule drugs for the treatment of the
most challenging infectious diseases. The Full Research Report on Achillion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/0af0_ACHN]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(480)-745-7826

SOURCE Investors-Alliance